Shares of AngioDynamics Inc. (NASDAQ:ANGO) hit a new 52-week high on Tuesday . The stock traded as high as $17.05 and last traded at $16.84, with a volume of 56,802 shares traded. The stock had previously closed at $16.83.

Separately, Zacks Investment Research upgraded AngioDynamics from a “sell” rating to a “hold” rating in a research report on Thursday, August 11th. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $14.10.

The company’s 50-day moving average is $16.18 and its 200-day moving average is $13.23. The stock’s market capitalization is $602.42 million.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Wednesday, July 13th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.16 by $0.03. The firm earned $93.40 million during the quarter, compared to analysts’ expectations of $88.64 million. The business’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same period in the prior year, the business earned $0.14 earnings per share. Analysts anticipate that AngioDynamics Inc. will post $0.63 EPS for the current fiscal year.

In other news, major shareholder Avista Capital Partners Gp, Ll sold 2,241,000 shares of AngioDynamics stock in a transaction on Friday, August 5th. The stock was sold at an average price of $14.62, for a total value of $32,763,420.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director David F. Burgstahler sold 2,250,000 shares of the business’s stock in a transaction dated Friday, August 5th. The stock was sold at an average price of $14.62, for a total value of $32,895,000.00. Following the transaction, the director now owns 23,988 shares of the company’s stock, valued at $350,704.56. The disclosure for this sale can be found here.

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.